These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 38815057)
21. Triglyceride-Rich Lipoproteins and Their Remnants as Silent Promoters of Atherosclerotic Cardiovascular Disease and Other Metabolic Disorders: A Review. Sascău R; Clement A; Radu R; Prisacariu C; Stătescu C Nutrients; 2021 May; 13(6):. PubMed ID: 34067469 [TBL] [Abstract][Full Text] [Related]
22. Evidence supporting primary prevention of cardiovascular diseases with statins: Gaps between updated clinical results and actual practice. Bruckert E; Ferrières J Arch Cardiovasc Dis; 2014 Mar; 107(3):188-200. PubMed ID: 24613429 [TBL] [Abstract][Full Text] [Related]
24. The effects of statins on high-density lipoproteins. Schaefer EJ; Asztalos BF Curr Atheroscler Rep; 2006 Jan; 8(1):41-9. PubMed ID: 16455013 [TBL] [Abstract][Full Text] [Related]
25. Residual Atherosclerotic Cardiovascular Disease Risk: Focus on Non-High-Density Lipoprotein Cholesterol. Luo Y; Peng D J Cardiovasc Pharmacol Ther; 2023; 28():10742484231189597. PubMed ID: 37641208 [TBL] [Abstract][Full Text] [Related]
26. High Sensitivity C-reactive Protein (hsCRP) and its Implications in Cardiovascular Outcomes. Denegri A; Boriani G Curr Pharm Des; 2021; 27(2):263-275. PubMed ID: 32679014 [TBL] [Abstract][Full Text] [Related]
27. Safety Issues Associated With the Clinical Application of PCSK9 Inhibitors: Current Findings. Wang D; Zhang D Cardiol Rev; 2023 May-Jun 01; 31(3):155-161. PubMed ID: 35175957 [TBL] [Abstract][Full Text] [Related]
28. Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid. Chapman MJ; Zamorano JL; Parhofer KG Pharmacol Ther; 2022 Sep; 237():108172. PubMed ID: 35304222 [TBL] [Abstract][Full Text] [Related]
29. Clinical Outcomes in Trials Evaluating Lipid-Lowering Drugs. Butters J; Brown A; Griffith L; Kim S; Nicholls SJ Am J Cardiovasc Drugs; 2017 Dec; 17(6):447-452. PubMed ID: 28432573 [TBL] [Abstract][Full Text] [Related]
30. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention? Tenenbaum A; Fisman EZ Cardiovasc Diabetol; 2012 Nov; 11():140. PubMed ID: 23150952 [TBL] [Abstract][Full Text] [Related]
32. Molecular Biological and Clinical Understanding of the Statin Residual Cardiovascular Disease Risk and Peroxisome Proliferator-Activated Receptor Alpha Agonists and Ezetimibe for Its Treatment. Yanai H; Adachi H; Hakoshima M; Katsuyama H Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408799 [TBL] [Abstract][Full Text] [Related]
33. National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report. Jacobson TA; Ito MK; Maki KC; Orringer CE; Bays HE; Jones PH; McKenney JM; Grundy SM; Gill EA; Wild RA; Wilson DP; Brown WV J Clin Lipidol; 2015; 9(2):129-69. PubMed ID: 25911072 [TBL] [Abstract][Full Text] [Related]
34. Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol. Xiao C; Dash S; Morgantini C; Hegele RA; Lewis GF Diabetes; 2016 Jul; 65(7):1767-78. PubMed ID: 27329952 [TBL] [Abstract][Full Text] [Related]
35. New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins. Kim K; Ginsberg HN; Choi SH Diabetes Metab J; 2022 Jul; 46(4):517-532. PubMed ID: 35929170 [TBL] [Abstract][Full Text] [Related]
36. A Clinical Guide to Combination Lipid-Lowering Therapy. Russell C; Sheth S; Jacoby D Curr Atheroscler Rep; 2018 Mar; 20(4):19. PubMed ID: 29516190 [TBL] [Abstract][Full Text] [Related]